Fact-checked by Grok 2 weeks ago

Pyruvate dehydrogenase

The (PDC), commonly known as pyruvate dehydrogenase, is a large multi-enzyme assembly residing in the of eukaryotic cells that catalyzes the irreversible oxidative of pyruvate to produce , , and NADH, serving as a critical link between and the tricarboxylic acid (TCA) cycle for ATP generation via . The PDC comprises three principal catalytic components—E1 (pyruvate dehydrogenase, a thiamine diphosphate-dependent enzyme that decarboxylates pyruvate), E2 (dihydrolipoyl transacetylase, which transfers the to ), and (dihydrolipoyl dehydrogenase, which reoxidizes the lipoamide cofactor using NAD⁺)—along with an E3-binding protein (E3BP) in eukaryotes to facilitate E3 attachment. In humans, the complex exhibits a pseudoicosahedral architecture with a core of 48 E2 subunits and 12 E3BP subunits, surrounded by 48 peripheral E1 heterotetramers (α₂β₂) and 12 E3 homodimers, yielding a total of about 9.5 and approximately 50 in , as determined by 2024 cryo-EM studies resolving the long-debated . This organized enables efficient channeling, where reactive intermediates are passed directly between tethered lipoyl domains of E2 without release into solution, as revealed by cryo-electron microscopy studies showing lipoyl domains embedded in the E2 catalytic . Activity of the PDC is tightly regulated to match cellular demands, primarily through reversible of the E1α subunit at three serine residues (Ser-232, Ser-293, and Ser-300 in bovine numbering) by four pyruvate dehydrogenase kinases (PDK1–4), which inactivate the complex, and reactivation via by two pyruvate dehydrogenase phosphatases ( and PDP2). Kinase activity is enhanced by high ratios of NADH/NAD⁺ and /CoA, as well as direct binding to the lipoyl domains of E2, while phosphatases are activated by calcium ions and insulin signaling; additionally, pyruvate and act as allosteric inhibitors of PDKs to promote PDC activation during glucose oxidation. This regulatory mechanism ensures metabolic flexibility, preventing futile cycling and adapting to states such as or exercise.

Overview

Biochemical Function

The pyruvate dehydrogenase complex (PDC) serves as the primary enzymatic gateway connecting to the tricarboxylic acid () cycle in aerobic , catalyzing the irreversible oxidative of pyruvate derived from glucose breakdown. This reaction commits pyruvate to oxidation rather than alternative fates such as formation under conditions, thereby enabling efficient ATP production through downstream mitochondrial processes. The PDC's activity is indispensable for sustaining cellular energy demands in most tissues, particularly those reliant on . The overall biochemical reaction mediated by the PDC is: \text{CH}_3\text{COCOO}^- \text{(pyruvate)} + \text{CoA} + \text{NAD}^+ \rightarrow \text{CH}_3\text{COSCoA (acetyl-CoA)} + \text{CO}_2 + \text{NADH} + \text{H}^+ This transformation generates acetyl-CoA, which enters the TCA cycle, while producing CO₂ as a byproduct and reducing NAD⁺ to NADH for the electron transport chain. The reaction is highly exergonic and unidirectional under physiological conditions, ensuring a one-way flux from carbohydrate catabolism to complete oxidation. The PDC operates as a large, multienzyme assembly comprising three principal catalytic components: E1 (pyruvate dehydrogenase), which performs the initial ; E2 (dihydrolipoyl transacetylase), which transfers the ; and E3 (dihydrolipoyl dehydrogenase), which regenerates the oxidized lipoyl cofactor while reducing NAD⁺. These subunits are organized in a tightly integrated that facilitates channeling, minimizing the release of reactive intermediates and enhancing catalytic efficiency. The complex requires five essential cofactors to execute its function: (TPP) bound to E1 for , covalently attached to E2 for acyl transfer, (CoA) as the acetyl acceptor, (FAD) on E3 for , and NAD⁺ as the terminal oxidant. Deficiencies in these cofactors, such as ( B1), can impair PDC activity and lead to metabolic disorders.

Role in Metabolism

The pyruvate dehydrogenase complex (PDC) serves as a critical gatekeeper in cellular metabolism, bridging the anaerobic process of glycolysis in the cytosol to the aerobic pathways of the tricarboxylic acid (TCA) cycle and oxidative phosphorylation in the mitochondria. Under aerobic conditions, PDC catalyzes the oxidative decarboxylation of pyruvate—produced from glucose breakdown during glycolysis—into acetyl-CoA, which then enters the TCA cycle to generate additional reducing equivalents and carbon dioxide. This linkage ensures efficient oxidation of glucose-derived carbons, directing metabolic flux toward complete energy extraction rather than partial fermentation. A key outcome of PDC activity is the production of NADH, a vital reducing equivalent that fuels the in the , ultimately driving ATP synthesis through . For each pyruvate molecule processed, PDC generates one NADH molecule alongside , contributing substantially to the cell's proton gradient and energy yield—approximately 15 ATP per pyruvate via this route when combined with TCA cycle outputs (classical estimate). The reaction mediated by PDC represents an irreversible commitment of glucose-derived carbon to oxidative , as the step eliminates CO₂ and prevents the reversal of back to pyruvate, thereby blocking from these intermediates. This one-way flux conserves metabolic resources by favoring energy production over biosynthetic reversal, ensuring that pyruvate is not diverted to glucose synthesis under fed or aerobic states. In contrast, under anaerobic conditions—such as or high glycolytic flux—PDC activity is inhibited, primarily through by pyruvate dehydrogenase kinases, redirecting pyruvate toward to produce and regenerate NAD⁺ for continued while conserving pyruvate as a potential fuel or biosynthetic precursor.

Structure

Overall Complex Architecture

The pyruvate dehydrogenase complex (PDC) is a massive multienzyme assembly with a total molecular weight of approximately 9–10 MDa in mammals, facilitating the coordinated oxidation of pyruvate to . This large size enables efficient substrate channeling, where intermediates are passed directly between enzyme active sites via flexible linkers, minimizing their diffusion into the surrounding medium and enhancing catalytic efficiency. The central scaffold of the PDC is formed by the dihydrolipoyl transacetylase (E2) component, which assembles into a highly symmetric oligomeric core. In bacterial species such as , this core exhibits cubic (octahedral) symmetry, consisting of 24 E2 subunits organized as eight homotrimers at the vertices, with an inner cavity diameter of about 60 Å. In contrast, eukaryotic PDCs feature a pseudoicosahedral core of 60 subunits, comprising 48 E2 and 12 E3-binding protein (E3BP) arranged in 20 heterotrimers, resulting in a larger inner cavity of approximately 120 Å. Recent cryo-EM structures reveal a tetrahedral arrangement of E3BP within the core and heterogeneous peripheral binding of E1 and , with stoichiometries varying by tissue and preparation. The pyruvate dehydrogenase (E1) and dihydrolipoyl dehydrogenase () enzymes attach peripherally to this through specific domains. Bacterial PDCs typically incorporate 12 E1 homodimers and 6 homodimers bound to the E2 , while eukaryotic versions bind 20–48 E1 heterotetramers and 4–12 homodimers via interactions with the peripheral subunit- domains on E2 and E3BP. These attachments are facilitated by the lipoyl domains on long, flexible "swinging arms" extending from E2, which shuttle hydroxyethyl-thiamine and other intermediates between the E1, E2, and active sites to support channeling. Stoichiometry varies across organisms, with bacterial PDCs maintaining a relatively fixed of 24 E2, 24 E1, and 12 subunits, whereas eukaryotic complexes exhibit more variability (e.g., average ratios of 21 E1 tetramers : 60 E2/E3BP subunits : 4 homodimers in porcine heart).

Subunits and Components

The (PDC) consists of three principal enzymatic subunits—E1, E2, and —that cooperate in the oxidative of pyruvate to , along with associated cofactors and, in eukaryotes, regulatory enzymes. The E1 subunit, known as pyruvate dehydrogenase, is a heterotetramer composed of two α and two β subunits (α₂β₂) in eukaryotes, with a molecular weight of approximately 154 kDa. It catalyzes the initial of pyruvate, utilizing (TPP) as a cofactor bound at the to facilitate the release of CO₂ and formation of a hydroxyethyl-TPP . In prokaryotes, E1 is typically a homodimer (α₂). The E2 subunit, or dihydrolipoyl transacetylase, forms the structural core of the PDC and is multimeric, assembling into a dodecahedral cage of 60 subunits in mammalian complexes, each with a molecular weight of about 60-70 kDa per full chain. E2 features multiple domains, including one to three tandem lipoyl domains that undergo swinging-arm motion, a peripheral subunit-binding domain, and a C-terminal catalytic domain responsible for acetyltransferase activity, which transfers the from the lipoyl moiety to . The core provides the scaffold for E1 and E3 attachment, with flexible linkers enabling substrate channeling. The E3 subunit, dihydrolipoyl , functions as a homodimer with each subunit approximately 50 kDa, yielding a total molecular weight of about 100 kDa, and contains binding sites for (FAD) and (NAD⁺). It reoxidizes the dihydrolipoyl groups on E2 by transferring electrons via FAD to NAD⁺, producing NADH, and is shared among multiple α-keto acid complexes, including the α-ketoglutarate and branched-chain α-keto acid complexes. In eukaryotic PDC, loosely associated regulatory components such as pyruvate dehydrogenase kinase (PDK) and pyruvate dehydrogenase phosphatase (PDP) are present but absent in prokaryotic complexes. Lipoic acid serves as a key swinging-arm cofactor, covalently attached via an amide bond to the ε-amino group of conserved lysine residues within the lipoyl domains of the E2 subunit (and E3-binding protein in some eukaryotes), enabling acetyl and electron transfer between active sites. TPP binds non-covalently to E1, while FAD is bound to E3 via a redox-active disulfide.

Mechanism

Overall Reaction

The pyruvate dehydrogenase complex (PDC) catalyzes the irreversible oxidative decarboxylation of pyruvate, a three-carbon α-keto acid, to form acetyl-coenzyme A (acetyl-CoA), a key intermediate that links glycolysis to the citric acid cycle, while simultaneously reducing NAD⁺ to NADH. This transformation is essential for aerobic metabolism, as it commits pyruvate to oxidation rather than fermentation pathways. The stoichiometry of the overall reaction is as follows: \text{pyruvate} + \text{[CoA](/page/COA)} + \text{NAD}^+ \rightarrow \text{[acetyl-CoA](/page/Acetyl-CoA)} + \text{[CO}_2](/page/Carbon_dioxide) + \text{NADH} + \text{H}^+ This balanced equation reflects the net consumption of one molecule each of pyruvate, (CoA), and NAD⁺, producing one molecule each of acetyl-CoA, (CO₂), and NADH. Through subsequent , the NADH generated yields approximately 2.5 ATP molecules, contributing to a total energy output of 12.5 ATP equivalents per pyruvate oxidized (including downstream contributions), markedly higher than the net 2 ATP from alone. The reaction proceeds optimally at neutral pH, around 7.4–7.6 in mammalian systems, and requires magnesium ions (Mg²⁺) to facilitate the function of thiamine pyrophosphate (TPP), a critical cofactor bound to the E1 subunit. The PDC employs multiple cofactors, including TPP, lipoic acid, CoA, flavin adenine dinucleotide (FAD), and NAD⁺, to achieve this coordinated multi-enzyme process.

Catalytic Steps

The pyruvate dehydrogenase complex catalyzes the oxidative decarboxylation of pyruvate through a coordinated sequence of four enzymatic steps involving its core components: pyruvate dehydrogenase (E1), dihydrolipoyl transacetylase (E2), and dihydrolipoyl dehydrogenase (E3). These steps utilize cofactors (TPP), lipoamide, (CoA), (FAD), and (NAD⁺) to generate , CO₂, and NADH without releasing reactive intermediates into solution. In the first step, E1 binds pyruvate and TPP, facilitating to release CO₂ and form hydroxyethyl-TPP as an intermediate. This reaction proceeds via nucleophilic attack by the TPP on the carbonyl carbon of pyruvate, followed by elimination of CO₂ and to yield the hydroxyethyl bound to TPP. The second step involves transfer of the hydroxyethyl group from hydroxyethyl-TPP on E1 to the oxidized lipoamide cofactor attached to a residue on E2, regenerating TPP and forming acetyl-dihydrolipoamide-E2. This reductive reduces the bond in lipoamide to a dithiol, with the thioesterified to one atom. In the third step, E2 catalyzes the transacetylation of the acetyl group from acetyl-dihydrolipoamide-E2 to , producing and leaving dihydrolipoamide-E2. This thiolysis reaction exploits the higher reactivity of the thiol compared to the dihydrolipoamide dithiol, ensuring efficient acetyl transfer. The fourth step is performed by , which reoxidizes dihydrolipoamide-E2 back to lipoamide-E2, transferring electrons first to its bound cofactor to form FADH₂, then to NAD⁺ to yield NADH and H⁺. This flavin-mediated reoxidation restores the disulfide in lipoamide, completing the cycle and enabling continuous turnover. Throughout these steps, substrate channeling is achieved via flexible, swinging lipoyl domains on E2, which intermediates between the active sites of E1, E2, and , preventing diffusion of reactive species and enhancing catalytic efficiency.

Regulation

Phosphorylation Control

The of the pyruvate dehydrogenase (PDH) complex by represents a primary covalent modification mechanism that toggles its enzymatic activity, enabling rapid adaptation to metabolic demands such as nutrient availability. Inactivation occurs through of the E1α subunit (encoded by PDHA1) by pyruvate dehydrogenase kinases (PDKs), while reactivation is achieved via by pyruvate dehydrogenase phosphatases (PDPs). This reversible process was first identified in the late 1960s as a key example of by covalent modification, with the specific sites on E1α mapped in the 1980s. PDKs catalyze the transfer of from ATP to three conserved serine residues on the E1α subunit—Ser232, Ser293, and Ser300 in the PDHA1 protein—resulting in conformational changes that inhibit the of pyruvate. at any single one of these sites is sufficient to fully inactivate the PDH complex, preventing production and redirecting pyruvate toward alternative pathways like formation or . In contrast, PDPs hydrolyze these groups to restore E1α activity; PDP function is magnesium-dependent (Mg²⁺ as a cofactor) and strongly stimulated by calcium ions (Ca²⁺), which enhance affinity and activity in response to cellular signals like . Mammals express four PDK isoforms (PDK1 through PDK4), each exhibiting tissue-specific expression patterns that fine-tune PDH regulation according to local metabolic needs; for instance, PDK1 predominates in the heart, while PDK4 is highly expressed in and liver. PDK4 expression is particularly upregulated during , leading to enhanced and PDH inactivation in muscle to conserve glucose for vital organs. Hormonal signals further modulate this system: insulin promotes PDH activation by stimulating PDP activity and suppressing PDK expression, whereas glucagon inhibits PDH through cAMP-mediated activation of PDKs, favoring oxidation in the fed-to-fasted transition. Allosteric effectors, such as pyruvate and , can indirectly influence PDK activity to reinforce control.

Allosteric Modulation

The pyruvate dehydrogenase complex (PDC) undergoes allosteric modulation primarily through product inhibition by its end products, NADH and , which reduce catalytic activity when cellular energy levels are high. NADH binds to the subunit (dihydrolipoyl dehydrogenase), competing with NAD⁺ for the and thereby inhibiting the reoxidation of the lipoamide cofactor, while binds to the E2 subunit (dihydrolipoyl transacetylase), competing with and hindering acetyl transfer. This competitive feedback mechanism ensures that PDC flux decreases under conditions of ample reducing equivalents and acetyl units, such as during oxidation or high ATP states. Pyruvate, the primary , indirectly activates PDC by allosterically inhibiting (PDK), which otherwise phosphorylates and inactivates the E1 subunit. Conversely, ATP promotes PDC inhibition by stimulating PDK activity, signaling energy sufficiency, whereas and NAD⁺ counteract product inhibition by favoring the forward reaction and relieving competitive binding at E2 and sites, respectively. The complex exhibits a Km for pyruvate of approximately 0.2–0.3 , reflecting its physiological sensitivity to substrate availability, and PDC activity is markedly reduced at elevated NADH/NAD⁺ ratios, amplifying inhibition during imbalance. This form of non-covalent regulation provides rapid, reversible control that complements covalent modifications like . Such allosteric mechanisms are evolutionarily conserved, with bacterial PDC displaying analogous product inhibition by NADH and to coordinate carbon flux in prokaryotes.

Genetics and Isoforms

Encoding Genes

The pyruvate dehydrogenase (PDH) complex in humans is encoded by multiple , each responsible for specific subunits or regulatory components. The E1α subunit is encoded by PDHA1, located on the at band p22.12. The E1β subunit is encoded by PDHB on at band p13. The E2 subunit, dihydrolipoamide acetyltransferase, is encoded by DLAT on at band q23.1. The E3 subunit, dihydrolipoamide dehydrogenase, is encoded by DLD on at band q31.1. The E3-binding protein (E3BP) is encoded by PDHX on at band p13. Regulatory kinases include PDK1 on at q31.1, PDK2 on chromosome 17 at q21.33, PDK3 on the at p22.11, and PDK4 on at q21.3. In bacteria such as , homologs of the PDH complex subunits are encoded by genes organized in the operon: aceE for the E1 component (pyruvate ), aceF for the E2 component (dihydrolipoamide acetyltransferase), and lpd (also known as lpdA) for the E3 component (dihydrolipoamide ). Pathogenic variants in these genes underlie PDH complex deficiencies, with PDHA1 being the most frequently affected. Over 100 distinct PDHA1 variants have been identified, predominantly missense mutations that disrupt enzyme function. These missense mutations often cluster in the thiamine pyrophosphate (TPP)-binding domain of the E1α subunit, impairing cofactor binding and catalytic activity. Recent genetic studies using CRISPR/Cas9 technology have demonstrated the essential role of PDHA1. Global knockout of Pdha1 in mice results in embryonic lethality around day 9.5 post-coitum, highlighting its critical function in early development. Alternative splicing of PDHA1 transcripts can generate isoforms, though the predominant form encodes the mitochondrial E1α subunit.

Tissue-Specific Expression

The pyruvate dehydrogenase complex (PDC) exhibits tissue-specific expression patterns primarily through distinct isoforms of its subunits, enabling adaptation to varying metabolic demands across cell types. The E1α subunit is encoded by two genes: PDHA1, which is ubiquitously expressed in somatic tissues, and PDHA2, a testis-specific isoform restricted to germ cells and essential for . Similarly, the regulatory pyruvate dehydrogenase kinases (PDKs) comprise four isoforms with differential distribution; PDK1 predominates in the and , where it supports high-energy flux, while PDK4 is prominently expressed in the liver and , facilitating responses to nutritional shifts such as . These isoform distributions ensure that PDC activity aligns with tissue-specific energy requirements, with higher overall expression in oxidative tissues like the and compared to glycolytic ones like the liver under fed conditions, where PDC is suppressed to prioritize . Expression of PDC components is further modulated by alternative splicing and phosphatase isoforms, contributing to fine-tuned regulation. In PDHA1, alternative splicing variants can alter exons encoding regulatory serine phosphorylation sites, potentially influencing kinase sensitivity and PDC activation in specific cellular contexts. The pyruvate dehydrogenase phosphatases (PDPs), which dephosphorylate and activate PDC, include two main isozymes: PDP1 (catalytic subunit encoded by PDP1, with regulatory subunit encoded by PDPR) and PDP2 (catalytic subunit encoded by PDP2), both localized to the mitochondrial matrix to counteract PDK-mediated inhibition in energy-demanding tissues. These mechanisms underscore tissue-specific control, with elevated PDC expression in the brain and heart reflecting their reliance on oxidative phosphorylation, whereas hepatic expression diminishes in the fed state due to insulin-mediated PDK upregulation. Developmentally, PDHA1 expression increases post-implantation in embryos, supporting the metabolic shift from to as tissues differentiate. In models, PDHA1 transcripts peak during early pre-implantation stages but ramp up significantly after implantation to sustain in glucose-dependent environments.

Clinical and Pathological Aspects

Deficiency Disorders

Pyruvate dehydrogenase complex deficiency (PDCD), primarily caused by mutations in the PDHA1 gene, is a mitochondrial disorder that impairs the conversion of pyruvate to , leading to accumulation of pyruvate and . This condition follows an X-linked pattern, where hemizygous males and heterozygous females (due to skewed X-inactivation) are affected, with PDHA1 mutations accounting for approximately 80% of cases. The estimated incidence is about 1 in 50,000 live births. Clinical manifestations typically present in the neonatal or infantile period, featuring severe that can cause , , rapid breathing, and irregular heartbeat. Neurological symptoms are prominent, including , seizures, developmental delay, , and ; a subset of patients develops , characterized by bilateral lesions in the and . Brain imaging often reveals abnormalities such as agenesis or dysgenesis. Diagnosis involves biochemical testing showing elevated blood lactate and pyruvate levels with a normal lactate-to-pyruvate ratio (typically 10-20, distinguishing it from respiratory chain defects where the ratio exceeds 25), alongside reduced activity in fibroblasts, lymphocytes, or muscle biopsies. Confirmation relies on , such as targeted sequencing of PDHA1 or multigene panels for mitochondrial disorders. There is no cure for PDCD, but management focuses on a to bypass the metabolic block by promoting fat utilization for energy production, supplementation (300-900 mg/day) to potentially enhance residual enzyme activity in responsive cases, and dichloroacetate as an investigational inhibitor to activate the complex. Recent efforts include the FDA review of sodium dichloroacetate (SL1009) as an oral formulation for PDCD, which received a Complete Response Letter in September 2025; additionally, preclinical approaches using next-generation AAV capsids show promise in rescuing disease phenotypes in models (as of August 2025). Supportive interventions include physical and . is variable depending on severity and onset; neonatal forms carry high mortality (up to 60% before age 1 in severe cohorts), while milder presentations allow survival into adulthood, though most survivors experience persistent neurological impairments such as .

Associated Diseases

The pyruvate dehydrogenase complex (PDC) serves as a major autoantigen in (PBC), an autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts. The E2 subunit of PDC (PDC-E2) is the primary target, with anti-PDC-E2 antibodies detected in approximately 90-95% of PBC patients, contributing to immune-mediated biliary epithelial cell damage through molecular mimicry and loss of tolerance. These autoantibodies are highly specific for PBC and correlate with disease severity, highlighting PDC's role in autoimmune beyond enzymatic function. In cancer, dysregulation of pyruvate dehydrogenase (PDH) activity promotes metabolic reprogramming, notably the Warburg effect, where tumor cells favor aerobic . Upregulation of pyruvate dehydrogenase kinases (PDKs), often mediated by hypoxia-inducible factor 1α (HIF-1α) in hypoxic tumor microenvironments, phosphorylates and inhibits PDH, diverting pyruvate from mitochondrial oxidation to production and supporting rapid . This PDK-PDHA1 axis is overexpressed in various solid tumors, including breast and cancers, enhancing tumor survival under nutrient stress. Conversely, PDH hyperactivation, by increasing mitochondrial pyruvate flux, sensitizes cells to oncogene-induced , acting as a tumor-suppressive mechanism; for instance, BRAF^{V600E}-driven PDH activation in triggers via and DNA damage. Neurological implications of PDH dysregulation extend to (AD), where reduced PDH activity disrupts neuronal energy metabolism and correlates with amyloid-β plaque accumulation. In AD models and postmortem brain tissue, amyloid-β oligomers inhibit PDH through oxidative modification, leading to impaired production and mitochondrial dysfunction that exacerbates synaptic loss and cognitive decline. A 2009 study in the 3xTg-AD mouse model demonstrated decreased PDH levels preceding amyloid pathology, underscoring its role in early bioenergetic deficits. Aging-associated decline in PDH activity contributes to mitochondrial dysfunction, particularly in , where it impairs and accelerates . Studies indicate a progressive reduction in PDH flux with age, linked to increased PDK expression and oxidative damage, resulting in diminished ATP production and . This metabolic shift, observed in elderly human muscle biopsies, aligns with broader mitochondrial impairments that drive age-related frailty. Therapeutic strategies targeting PDH dysregulation show promise in these pathologies. Dichloroacetate (DCA), a PDK that activates PDH, has been evaluated in phase II clinical trials for cancer, including a 2022 study combining DCA with chemoradiotherapy for locally advanced head and neck , demonstrating safety and potential to reverse metabolism without compromising treatment delivery. In PBC, high-dose supplementation, which supports PDH as a cofactor, has been trialed for symptom relief such as , with ongoing research exploring its role in mitigating autoimmune-mediated metabolic , though a 2024 placebo-controlled study found no significant benefit over placebo after four weeks.

Comparative and Evolutionary Aspects

Prokaryotic vs. Eukaryotic Forms

The (PDC) in prokaryotes exhibits a simpler architecture compared to its eukaryotic counterpart. In such as , the complex consists of three enzyme components—E1 (pyruvate dehydrogenase), E2 (dihydrolipoamide acetyltransferase), and E3 (dihydrolipoamide dehydrogenase)—assembled in a of approximately 24:24:12 (E1:E2:E3), forming a cubic core structure with and a total mass of about 4.5–5 MDa. This bacterial PDC lacks dedicated regulatory kinases and phosphatases, relying primarily on allosteric modulation for control, and is freely soluble in the without compartmentalization. In contrast, eukaryotic PDCs are significantly larger and more intricate, reaching masses of approximately 9–10 , as seen in fungal and mammalian forms. These complexes incorporate an additional component, E3-binding protein (E3BP), which facilitates docking, resulting in a pseudoicosahedral core composed of 48–60 E2 subunits and 12 E3BP subunits, binding 20–48 E1 heterotetramers and 6–12 dimers. Eukaryotic PDCs are localized to the , where nuclear-encoded subunits feature N-terminal mitochondrial targeting presequences that direct import and cleavage for assembly. is enhanced by dedicated pyruvate dehydrogenase kinases (PDKs) and phosphatases (PDPs), enabling covalent / of E1 at specific serine residues in response to hormonal and metabolic signals, a mechanism absent in prokaryotes. Evolutionarily, the eukaryotic PDC traces its origins to an alphaproteobacterial acquired via endosymbiosis during , with core components transferred to the host through endosymbiotic gene transfer. events in the eukaryotic lineage allowed a single E3 isoform to be shared among the PDC, 2-oxoglutarate dehydrogenase complex, and , contrasting with the more specialized, non-shared E3 variants often found in . This reflects increased regulatory complexity in eukaryotes tied to compartmentalized aerobic . Functionally, bacterial PDCs are less tightly regulated and can operate under varying oxygen conditions, though activity is typically repressed in favor of alternative pathways like pyruvate-formate lyase for production. Eukaryotic PDCs, confined to mitochondria, are more stringently controlled to integrate with , showing minimal activity under anaerobic stress due to PDK-mediated inactivation. Metagenomic studies indicate high conservation of bacterial PDH genes across diverse environments, while exhibit variations, often substituting the full with simpler pyruvate:ferredoxin oxidoreductases for formation. The pyruvate dehydrogenase complex (PDC) shares structural and functional similarities with several other enzyme complexes involved in oxidative reactions within metabolic pathways. Notably, the α-ketoglutarate dehydrogenase complex (KGDHC), also known as 2-oxoglutarate dehydrogenase complex, operates in the , catalyzing the conversion of α-ketoglutarate to and CO₂. Like PDC, KGDHC consists of E1 (α-ketoglutarate dehydrogenase), E2 (dihydrolipoamide succinyltransferase), and E3 (dihydrolipoamide dehydrogenase) components, with shared E2 and E3 subunits between the two complexes in eukaryotes, facilitating similar swinging-arm mechanisms for substrate transfer via lipoamide. Both employ (TPP) in their E1 components for , though KGDHC lacks the step specific to PDC. Another closely related complex is the branched-chain α-keto acid dehydrogenase (BCKDH), a mitochondrial responsible for the of branched-chain (leucine, , and ) by decarboxylating their corresponding α-keto acids to derivatives. BCKDH mirrors PDC in its multienzyme architecture, with homologous E1, E2, and E3 subunits, and shares the same E3 component in mammalian cells. Its regulation involves phosphorylation by a dedicated kinase, BCKDK, which is analogous to (PDK) in inhibiting activity under high substrate conditions. Deficiencies in BCKDH, particularly affecting the E3 subunit, lead to (MSUD), an inborn error of metabolism that can secondarily impair PDC and KGDHC function due to the shared E3, resulting in elevated branched-chain and . In plants, additional isoforms of the contribute to metabolic flexibility, particularly in maintaining redox balance. For instance, expresses two mitochondrial E2 isoforms (E2-OGDH1 and E2-OGDH2) for KGDHC, with E2-OGDH2 being predominant and both influencing carbon-nitrogen assimilation by modulating NADH production and flux. These isoforms allow plants to adjust respiratory rates and in response to environmental stresses, such as darkness, without disrupting overall . A non-homologous enzyme performing a related reaction is bacterial pyruvate oxidase (EC 1.2.3.3), which oxidatively decarboxylates pyruvate to acetyl phosphate, CO₂, and H₂O₂ in an oxygen-dependent manner, bypassing CoA involvement unlike PDC. This flavin-dependent supports acetate production and generation in prokaryotes, highlighting divergent evolutionary paths for pyruvate oxidation. The component of PDC (dihydrolipoamide dehydrogenase) is also shared with the (GCS), a mitochondrial complex that decarboxylates to produce 5,10-methylene-tetrahydrofolate, CO₂, and NH₃ during in and one-carbon metabolism in animals. This overlap enables coordinated regulation of nitrogen and carbon fluxes, with E3 deficiencies impacting both PDC and GCS activities.

References

  1. [1]
    The Pyruvate Dehydrogenase Complexes: Structure-based Function ...
    The pyruvate dehydrogenase complex (PDC) catalyzes the oxidative decarboxylation of pyruvate with the formation of acetyl-CoA, CO2 and NADH (H+) (1–3). The PDC ...
  2. [2]
    Stoichiometry and architecture of the human pyruvate ...
    Jul 17, 2024 · The pyruvate dehydrogenase complex (PDHc) is a multienzyme assembly that links the two major metabolic pathways of glycolysis and citric acid ...<|control11|><|separator|>
  3. [3]
    Structure of the native pyruvate dehydrogenase complex reveals the ...
    Sep 6, 2021 · This structure provides molecular details of the assembly of the core and reveals how the lipoyl domains interact with the core at the active site.
  4. [4]
    Pyruvate Dehydrogenase Complex: Metabolic Link to Ischemic ... - NIH
    The mammalian pyruvate dehydrogenase complex (PDHC) is a mitochondrial matrix enzyme complex (greater than 7 million Daltons) that catalyzes the oxidative ...Missing: definition | Show results with:definition
  5. [5]
    The Pyruvate Dehydrogenase Complex in Sepsis: Metabolic ...
    The pyruvate dehydrogenase complex (PDHC) is a multienzyme complex that serves as a critical hub in energy metabolism. Under aerobic conditions, pyruvate ...
  6. [6]
  7. [7]
    Role of the Pyruvate Dehydrogenase Complex in Metabolic ...
    Aug 21, 2018 · In this review, we will summarize the roles of PDC in diverse tissues and how regulation of its activity is affected in various metabolic disorders.Missing: equation | Show results with:equation
  8. [8]
    Stoichiometry and architecture of the human pyruvate ... - Science
    Jul 17, 2024 · In Gammaproteobacteria (e.g., Escherichia coli), the PDHc core is a cubic ~1.5-MDa homo-oligomer of 24 E2 subunits (8 E2 homotrimers) to which a ...
  9. [9]
    Structural diversity of pyruvate dehydrogenase complexes - Bothe
    Aug 13, 2025 · The pyruvate dehydrogenase complex (PDHc) is a crucial metabolic enzyme complex found in all aerobic organisms. It catalyzes the conversion ...Abstract · Abbreviations · Different PDHc core... · Peripheral subunits and their...
  10. [10]
    Dynamics of the mammalian pyruvate dehydrogenase complex ...
    Jan 22, 2025 · The multi-enzyme pyruvate dehydrogenase complex (PDHc) links glycolysis to the citric acid cycle and plays vital roles in metabolism, energy production, and ...
  11. [11]
    The remarkable structural and functional organization of the ... - PNAS
    The cut-away structure of the three pyruvate dehydrogenase tetramers (α2β2, Mr ≈ 154,000) bound to an E2 inner core trimer (Mr ≈ 81,000) shows that these ...Missing: heterotetramer | Show results with:heterotetramer<|control11|><|separator|>
  12. [12]
    Sidechain Biology and the Immunogenicity of PDC-E2, the Major ...
    Subsequently, lipoic acid is covalently attached to the E2 subunit conferring ... Specific lysine residue where lipoic acid is attached via an amide bond.
  13. [13]
    Subunit stoichiometry and molecular weight of the pyruvate ... - PNAS
    dehydrogenase complex. The pyruvate dehydrogenase multienzyme complex from. Escherichia coli catalyzes the overall reaction. Pyruvate + NAD+ + CoA. -- Acetyl ...
  14. [14]
    The Pyruvate Dehydrogenase Complexes: Structure-based Function ...
    The pyruvate dehydrogenase complex (PDC) catalyzes the oxidative decarboxylation of pyruvate with the formation of acetyl-CoA, CO2 and NADH (H+) (1, 2, 3). The ...
  15. [15]
    Pyruvate Dehydrogenase Complex and TCA Cycle
    A mnemonic that helps one remember these five required co-factors/coenzymes is Tender (TPP) Loving (lipoic acid) Care (CoA) For (FAD) Nancy (NAD+). Three of the ...
  16. [16]
    [PDF] Basic properties of the pyruvate dehydrogenase complex isolated ...
    In this case the pH optimum was shifted towards the pH value of 7.4 and 7.6 in phosphate and Tris/HCl buffer, respectively. It is possible that ionization ...<|control11|><|separator|>
  17. [17]
    The Pyruvate-Dehydrogenase Complex from Azotobacter vinelandii
    Fig1 also shows that the dependence of thc activity on the Mg2+ -TPP concentration is greatly influenced by the presence of AMP and the reaction product.
  18. [18]
    [PDF] Pyruvate Oxidation - Rose-Hulman
    The complex is comprised of three separate enzymes involved in the actual catalytic process, and uses a total of five different cofactors. The large size of the ...
  19. [19]
    Snapshots of Catalysis in the E1 Subunit of the Pyruvate ...
    Dec 9, 2008 · E2p catalyzes the transfer of the acetyl group from the lipoyl domain to CoA creating acetyl CoA, and E3 regenerates the disulphide bond in the ...
  20. [20]
    [PDF] Molecular architecture and mechanism of an icosahedral pyruvate ...
    Multi-enzyme complexes in the 2-oxo acid dehydrogenase family of multi-functional enzymes catalyse multi-step oxidative decarboxylations that furnish several of ...
  21. [21]
    Structural Basis for Inactivation of the Human Pyruvate ... - NIH
    SUMMARY. We report the crystal structures of the phosporylated pyruvate dehydrogenase (E1p) component of the human pyruvate dehydrogenase complex (PDC).
  22. [22]
    Monitoring phosphorylation of the pyruvate dehydrogenase complex
    Although regulation of the mammalian PDH by reversible phosphorylation has been studied since the late 1960's, the development of phospho-specific ...
  23. [23]
    PDHA1 - Pyruvate dehydrogenase E1 component subunit ... - UniProt
    Recommended name. Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial · EC number. EC:1.2.4.1 (UniProtKB | ENZYME | Rhea ).Missing: TPP weight
  24. [24]
    Role of the regulatory subunit of bovine pyruvate dehydrogenase ...
    May 14, 1996 · Bovine pyruvate dehydrogenase phosphatase (PDP) is a Mg2+-dependent and Ca2+-stimulated heterodimer that is a member of the protein ...Missing: Ca2+ | Show results with:Ca2+
  25. [25]
    Role of the regulatory subunit of bovine pyruvate dehydrogenase ...
    1, Ca2+ increased the sensitivity of both PDP and PDPc to Mg2+. In the absence of Ca2+, the Km of PDP and PDPc for Mg2+ increased to about. 3.5 and 2.6 mM ...
  26. [26]
    Evidence for existence of tissue-specific regulation ... - Portland Press
    It appeared that expression of these isoenzymes occurs in a tissue-specific manner. The mRNA for isoenzyme PDK1 was found almost exclusively in rat heart. The ...
  27. [27]
    Adaptive increase in pyruvate dehydrogenase kinase 4 during ...
    Pyruvate dehydrogenase kinase isoform 4 (PDK4) is upregulated by starvation in many tissues of the body during starvation. This causes inactivation of the ...
  28. [28]
    Regulation of Pyruvate Dehydrogenase Kinase Expression by ...
    Feb 1, 2002 · Two isoforms of this mitochondrial kinase (PDK2 and PDK4) are induced in a tissue-specific manner in response to starvation and diabetes.
  29. [29]
    Regulation of Muscle Pyruvate Dehydrogenase Complex in Insulin ...
    Oct 17, 2013 · The activation status of the PDC is controlled covalently via phosphorylation-dephosphorylation of three serine residues (Ser232, Ser293, Ser300) ...
  30. [30]
    Regulation of the activity of the pyruvate dehydrogenase complex
    The pyruvate dehydrogenase complex catalyzes the irreversible oxidative decarboxylation of pyruvate to form acetyl-CoA. This reaction links glycolysis and ...
  31. [31]
    Regulation of the pyruvate dehydrogenase complex - PubMed
    ### Summary of Regulation of the Pyruvate Dehydrogenase Complex (PMID: 16545080)
  32. [32]
    Regulation of pyruvate metabolism and human disease - PMC
    Over a sequence of reactions, the pyruvate dehydrogenase complex (PDH) irreversibly converts pyruvate and NAD+ into acetyl-CoA, NADH, and carbon dioxide. The ...
  33. [33]
  34. [34]
    The pyruvate-dehydrogenase complex from Azotobacter vinelandii
    Nov 15, 1975 · The pyruvate dehydrogenase complex from Axotobacter vinelandii was isolated in a five-step procedure ... Km(pyruvate)0.3 mM. The kinetics ...
  35. [35]
    Emerging roles of pyruvate dehydrogenase phosphatase 1 - Frontiers
    May 25, 2025 · In this review, we discuss recent studies revealing the crucial role of PDP1 and its dysregulation in various metabolic disorders.
  36. [36]
    PDHA1 pyruvate dehydrogenase E1 subunit alpha 1 [ (human)] - NCBI
    Sep 9, 2025 · Phosphorylation at distinct serine and tyrosine residues inhibits PDHA1 through distinct mechanisms to impact active site accessibility.
  37. [37]
    PDHB pyruvate dehydrogenase E1 subunit beta [ (human)] - NCBI
    This gene encodes the E1 beta subunit. Mutations in this gene are associated with pyruvate dehydrogenase E1-beta deficiency.Missing: chromosome | Show results with:chromosome
  38. [38]
    1738 - Gene ResultDLD dihydrolipoamide dehydrogenase [ (human)]
    Sep 9, 2025 · This gene encodes a member of the class-I pyridine nucleotide-disulfide oxidoreductase family. The encoded protein has been identified as a ...Missing: chromosome | Show results with:chromosome<|separator|>
  39. [39]
    PDK1 pyruvate dehydrogenase kinase 1 [ (human)] - NCBI
    Pyruvate dehydrogenase kinase 1 is an important regulator of pyruvate dehydrogenase in clonal pancreatic beta-cells. Observational study of gene ...
  40. [40]
    PDK2 pyruvate dehydrogenase kinase 2 [ (human)] - NCBI
    Aug 19, 2025 · Germline mutations in PKD2 gene is associated with autosomal-dominant polycystic kidney disease. we for the first time demonstrated that a low- ...Missing: chromosomal | Show results with:chromosomal
  41. [41]
    PDK4 pyruvate dehydrogenase kinase 4 [ (human)] - NCBI
    Sep 14, 2025 · This gene is a member of the PDK/BCKDK protein kinase family and encodes a mitochondrial protein with a histidine kinase domain.Missing: chromosomal | Show results with:chromosomal
  42. [42]
    The pdhR-aceEF-lpd operon of Escherichia coli ... - PubMed
    The pdhR gene (formerly genA) is the proximal gene of the pdhR-aceE-aceF-lpd operon encoding the pyruvate dehydrogenase (PDH) complex of Escherichia coli.
  43. [43]
    Somatic mosaicism for a novel PDHA1 mutation in a male with ... - NIH
    About 90% of PDC deficiencies in genetically confirmed patients result from mutations in the X-linked PDHA1[2], [3]. More than 100 different mutations have been ...
  44. [44]
    Solvent accessibility of E1α and E1β residues with known missense ...
    Feb 1, 2022 · We collected 166 and 13 reported cases with PDCD due to missense mutations in PDHA1 and PDHB, respectively (Table S1A,B). Analysis of the ...
  45. [45]
    Conditional knockout of pyruvate dehydrogenase in mouse ...
    Knocking out the PDHA1 gene in the β-cells of adult male mice did not significant alter the body weight, fasting blood glucose, body shape or nutritional status ...
  46. [46]
    mRNA and protein expression patterns of E1α subunit genes in ...
    ▻ mRNA and protein expression patterns of genes encoding the α subunit of PDC. ▻ PDHA1 is expressed in somatic cells, whereas PDHA2 is restricted to germ cells.
  47. [47]
    Null mutations in the PDHX gene associated with unusual ... - PubMed
    Jun 22, 2016 · The E1α subunit exists as two isoforms encoded by different genes: PDHA1 located on Xp22.1 and expressed in somatic tissues, and the intronless ...
  48. [48]
    Testis‐Specific PDHA2 Is Required for Proper Meiotic ...
    Feb 20, 2025 · PDHA2 is the testis-specific paralog of PDHA1, a core subunit of pyruvate dehydrogenase. However, its role during spermatogenesis is unclear ...
  49. [49]
    Pyruvate Dehydrogenase Kinase-4 Structures Reveal a Metastable ...
    PDK isoforms exhibit tissue-specific expression; PDK1 is detected in heart, pancreatic islets, and skeletal muscles; PDK2 is expressed in all tissues; PDK3 ...
  50. [50]
    Pyruvate dehydrogenase kinases (PDKs): an overview toward ...
    Under normal conditions, pyruvate dehydrogenase phosphatase inhibits PDK and activates PDC, which then catalyzes pyruvate in the tricarboxylic acid cycle to ...
  51. [51]
    The pivotal role of pyruvate dehydrogenase kinases in metabolic ...
    Feb 12, 2014 · This review summarizes PDKs' pivotal role in control of metabolic flexibility under various nutrient conditions and in different tissues.Energy Deprivation · Long-Term High Fat Diet... · Insulin Resistance And...
  52. [52]
    Regulation of pyruvate metabolism and human disease
    Dec 21, 2013 · Rapid regulation of the PDH activity is achieved by phosphorylation and dephosphorylation, functions performed by the pyruvate dehydrogenase ...Cytosolic Pyruvate... · Pyruvate Kinase · Neurodegeneration
  53. [53]
    Splicing Error in E1α Pyruvate Dehydrogenase mRNA Caused by ...
    To date, there is no evidence for developmentally regulated alternative splicing events or tissue-specific control of the expression of this gene. This paper ...
  54. [54]
    The SR Protein SC35 Is Responsible for Aberrant Splicing of ... - NIH
    Alternative splicing enables the same precursor to give rise to several mRNAs that code for proteins having distinct functions. Thus, the precise selection of 5 ...
  55. [55]
    Analysis of Exonic Mutations Leading to Exon Skipping in Patients ...
    Dec 1, 2000 · In this work, we were able to demonstrate, by performing splicing experiments, that the two exonic mutations described in the PDH E1α gene lead to aberrant ...
  56. [56]
    Isoenzymes of Pyruvate Dehydrogenase Phosphatase: DNA ...
    Pyruvate dehydrogenase phosphatase (PDP) is one of the few mammalian phosphatases residing within the mitochondrial matrix space.
  57. [57]
    Isoenzymes of Pyruvate Dehydrogenase Phosphatase
    Pyruvate dehydrogenase phosphatase (PDP) is one of the few mammalian phosphatases residing within the mitochondrial matrix space.
  58. [58]
    Tissue-specific kinase expression and activity regulate flux through ...
    The pyruvate dehydrogenase complex (PDC) is a multienzyme assembly that converts pyruvate to acetyl-CoA. As pyruvate and acetyl-CoA play central roles in ...
  59. [59]
    Inactivation of the murine pyruvate dehydrogenase (Pdha1) gene ...
    Inactivation of Pdha1 caused smaller litters and delayed embryonic development, showing the importance of glucose metabolism during early prenatal development.Missing: expression | Show results with:expression
  60. [60]
    Nuclear accumulation of pyruvate dehydrogenase alpha 1 promotes ...
    Next, we measured PDHA1 expression levels during embryonic development and found that PDHA1 was highly expressed at the 4-cell and the 8-to-16-cell stages ...Missing: post- | Show results with:post-
  61. [61]
    Understanding Male Prevalence in Early Mouse Embryo Stages
    Expression analysis of X‐linked metabolic genes revealed stage‐specific patterns, with PDHA1 exhibiting the highest activity at the eight‐cell stage.<|separator|>
  62. [62]
  63. [63]
    Neurons require glucose uptake and glycolysis in vivo - PMC - NIH
    Pyruvate dehydrogenase has a major role in mast cell function, and its activity is regulated by mitochondrial microphthalmia transcription factor. J ...
  64. [64]
    Primary Pyruvate Dehydrogenase Complex Deficiency Overview
    Jun 17, 2021 · Primary PDCD caused by pathogenic variants in DLAT, DLD, PDHB, PDHX, or PDP1 is inherited in an autosomal recessive manner. X-Linked Inheritance ...Summary · Management of Pyruvate... · Genetic Risk Assessment of...
  65. [65]
    Pyruvate dehydrogenase deficiency: MedlinePlus Genetics
    Jul 1, 2012 · The pyruvate dehydrogenase complex is made up of multiple copies of several enzymes called E1, E2, and E3, each of which performs part of ...Missing: definition | Show results with:definition
  66. [66]
    Center For Human Genetics - July 2024 | School of Medicine
    Jul 16, 2024 · There is no cure, and only limited treatment options. It is frequently diagnosed late, despite an estimated incidence of 1 in 50,000 to 75,000 ...
  67. [67]
    Diagnostic accuracy of blood lactate-to-pyruvate molar ratio in the ...
    The blood lactate-to-pyruvate (L:P) molar ratio is used to distinguish between pyruvate dehydrogenase deficiency (PDH-D) and other causes of congenital lactic ...
  68. [68]
    Study Details | NCT02616484 | Trial of Dichloroacetate in Pyruvate ...
    PDC deficiency (PDCD) is the most common cause of congenital lactic acidosis and is a frequently fatal metabolic disease of childhood for which no proven ...
  69. [69]
    Spectrum of neurological and survival outcomes in pyruvate ...
    Sep 7, 2012 · Of these, 91% (21/23) died before age 4 years, 61% (14/23) before 1 year, and 43% (10/23) before 3 months. 56% of males died compared with 25% ...
  70. [70]
    Diagnosis and Management of Primary Biliary Cholangitis
    The serologic hallmark of PBC is the anti-mitochondrial antibody (AMA), a highly disease-specific auto-antibody detected in 90–95% of PBC patients and less than ...
  71. [71]
    Role of autoantibodies in the clinical management of primary biliary ...
    Mar 28, 2023 · Few AMA positive PBC patients react only towards PDC-E2 and even less solely to OGDC-E2 or BCOADC-E2. The predominant anti-M2 reactivity is the ...
  72. [72]
    Metabolic Flexibility in Cancer: Targeting the Pyruvate ...
    The PDK family of enzymes comprises four members (PDK1–PDK4) that are located in the mitochondrial matrix with approximately 70% homology between them (6). PDKs ...Missing: chromosomal | Show results with:chromosomal
  73. [73]
    A key role for mitochondrial gatekeeper pyruvate dehydrogenase in ...
    Jun 6, 2013 · The mitochondrial gatekeeper pyruvate dehydrogenase (PDH) is a crucial mediator of senescence induced by BRAF(V600E), an oncogene commonly mutated in melanoma ...Missing: hyperactivation | Show results with:hyperactivation
  74. [74]
    Mitochondrial dysfunction - the beginning of the end in Alzheimer's ...
    Moreover, Aβ disturbs the activity of several enzymes, such as pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase (αKGDH), decreasing NADH reduction ...
  75. [75]
    Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in ...
    Mitochondrial dysfunction in the 3xTg-AD brain was evidenced by decreased mitochondrial respiration and decreased pyruvate dehydrogenase (PDH) protein level and ...
  76. [76]
    Muscle mitochondrial changes with aging and exercise
    Substantial data support the view that mitochondrial function declines with old age. Indeed, oxidative capacity has been shown to be impaired with old age as ...
  77. [77]
    Phase II study of dichloroacetate, an inhibitor of pyruvate ...
    Dichloroacetate (DCA), a pyruvate dehydrogenase kinase metabolic inhibitor, reduces tumor lactate production and has been used in cancer therapy previously.
  78. [78]
    High-dose oral thiamine versus placebo for chronic fatigue in ...
    Mar 29, 2024 · Four weeks of high-dose oral thiamine treatment in patients with PBC was well tolerated and safe. However, high-dose thiamine was not superior to placebo in ...Missing: pyruvate dehydrogenase
  79. [79]
    Subunit stoichiometry and molecular weight of the pyruvate ... - PNAS
    The molecular weights of the complex, E1, and E3 were found to be 4,800,000, 182,000, and 104,000, respectively, with low-angle laser light scattering. Both E1 ...Missing: architecture | Show results with:architecture
  80. [80]
    Integrative structure of a 10-megadalton eukaryotic pyruvate ...
    Feb 9, 2021 · The pyruvate dehydrogenase complex (PDHc) is a giant enzymatic assembly involved in pyruvate oxidation. PDHc components have been ...
  81. [81]
    Chimeric origins and dynamic evolution of central carbon ... - Nature
    Mar 3, 2025 · Here we systematically analyse the evolutionary origins of the eukaryotic gene repertoires mediating central carbon metabolism.
  82. [82]
    Evolution of the enzymes of the citric acid cycle and the glyoxylate ...
    Feb 14, 2002 · Eukaryotic OGDH E3 is most similar to α-proteobacterial homologues. ... The two isoenzymes in the plant kingdom originated from a gene duplication ...
  83. [83]
    Pyruvate metabolism in aerobic and anaerobic bacteria. Under ...
    Under aerobic conditions, bacteria utilize pyruvate dehydrogenase to convert pyruvate into acetyl-CoA and carbon dioxide. Anaerobic bacteria can only grow ...
  84. [84]
    2-Oxoacid dehydrogenase multienzyme complexes in the halophilic ...
    All Archaea catalyse the conversion of pyruvate to acetyl-CoA via a simple pyruvate oxidoreductase. This is in contrast to the Eukarya and most aerobic ...Missing: variations | Show results with:variations
  85. [85]
  86. [86]
    Maple Syrup Urine Disease - StatPearls - NCBI Bookshelf
    Mar 3, 2024 · Patients usually have combined deficiencies of the E3 subunit and pyruvate/alpha-ketoglutarate dehydrogenase complexes. Clinically, patients ...
  87. [87]
    Downregulation of the E2 Subunit of 2-Oxoglutarate Dehydrogenase ...
    The functional lack of expression of E 2 subunit isoforms of 2-OGDH increased plant growth, reduced dark respiration and altered carbohydrate metabolism.
  88. [88]
    Pyruvate:Quinone Oxidoreductase from Corynebacterium glutamicum
    This type of enzyme (EC 1.2.3.3) catalyzes in a phosphate- and oxygen-dependent reaction the formation of acetyl-phosphate, CO2, and hydrogen peroxide and in ...
  89. [89]
    Glycine decarboxylase and pyruvate dehydrogenase complexes ...
    We conclude that, in pea leaf mitochondria, the pyruvate dehydrogenase and glycine decarboxylase complexes share the same dihydrolipoamide dehydrogenase. We ...